$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

$qlgn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224013400 Filed on April 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.057M	$962.8K	$6.096M
YoY Change	-44.74%	-67.09%	-48.28%
% of Gross Profit
Research & Development	$364.4K	$1.311M	$5.209M
YoY Change	-82.82%	-26.26%	-23.81%
% of Gross Profit
Depreciation & Amortization		$4.500K	$4.500K
YoY Change		-91.49%	-97.05%
% of Gross Profit
Operating Expenses	$1.422M	$2.274M	$11.30M
YoY Change	-73.17%	-51.65%	-58.38%
Operating Profit	-$1.422M		-$11.30M
YoY Change	-61.5%		-49.03%
Interest Expense	$68.00K	-$235.8K	-$1.525M
YoY Change	-112.49%	456.02%	5621.28%
% of Operating Profit
Other Income/Expense, Net	-$609.2K	$663.1K	$2.074M
YoY Change	5.35%	-693.03%	135.28%
Pretax Income	-$2.031M	-$2.472M	-$12.48M
YoY Change	-52.45%	-71.91%	-41.41%
Income Tax	$1.786K	-$4.790K	-$4.790K
% Of Pretax Income
Net Earnings	-$2.033M	-$2.450M	-$13.42M
YoY Change	-47.15%	-61.55%	-28.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.35	-$0.47	-$2.64
COMMON SHARES
Basic Shares Outstanding	6.307M shares	5.181M shares	5.073M shares
Diluted Shares Outstanding	5.944M shares		5.073M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.22K	$401.8K	$401.8K
YoY Change	-97.86%	-94.29%	-94.29%
Cash & Equivalents	$93.22K	$401.8K
Short-Term Investments
Other Short-Term Assets	$910.0K	$765.0K	$765.0K
YoY Change	7382.86%	5958.61%	-53.95%
Inventory
Prepaid Expenses
Receivables		$538.6K
Other Receivables
Total Short-Term Assets	$1.003M	$1.167M	$1.167M
YoY Change	-86.69%	-89.22%	-89.22%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$866.5K	$866.5K
YoY Change		4626.08%	3507.33%
Total Long-Term Assets	$0.00	$866.5K	$866.5K
YoY Change	-100.0%	-89.51%	-89.51%
TOTAL ASSETS
Total Short-Term Assets	$1.003M	$1.167M	$1.167M
Total Long-Term Assets	$0.00	$866.5K	$866.5K
Total Assets	$1.003M	$2.033M	$2.033M
YoY Change	-93.7%	-89.35%	-89.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.801M	$2.223M	$2.223M
YoY Change	100.16%	159.3%	159.3%
Accrued Expenses	$819.0K	$527.0K	$527.0K
YoY Change	-56.75%	-65.14%	-72.67%
Deferred Revenue
YoY Change
Short-Term Debt	$1.023M	$1.299M	$1.299M
YoY Change	6.67%	36.66%	36.66%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.525M	$4.137M	$4.137M
YoY Change	-45.12%	-51.94%	-51.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.525M	$4.137M	$4.137M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.525M	$4.137M	$4.137M
YoY Change	-53.42%	-59.9%	-65.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.8M	-$116.8M
YoY Change	10.82%	12.96%
Common Stock	$44.40K	$43.26K
YoY Change	3.37%	2.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.522M	-$2.104M	-$2.104M
YoY Change
Total Liabilities & Shareholders Equity	$1.003M	$2.033M	$2.033M
YoY Change	-93.7%	-89.35%	-89.35%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.033M	-$2.450M	-$13.42M
YoY Change	-47.15%	-61.55%	-28.02%
Depreciation, Depletion And Amortization		$4.500K	$4.500K
YoY Change		-91.49%	-97.05%
Cash From Operating Activities	-$783.6K	-$5.672M	-$10.30M
YoY Change	-69.86%	153.45%	-21.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$235.4K	$4.216M
YoY Change			3014.84%
Cash From Investing Activities		$235.4K	$4.216M
YoY Change		-196.33%	-2394.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$475.0K	-110.0K	-550.0K
YoY Change		-103.79%	-118.9%
NET CHANGE
Cash From Operating Activities	-$783.6K	-5.672M	-10.30M
Cash From Investing Activities		235.4K	4.216M
Cash From Financing Activities	$475.0K	-110.0K	-550.0K
Net Change In Cash	-$800.0K	-5.546M	-6.638M
YoY Change	-71.75%	-1416.6%	-36.9%
FREE CASH FLOW
Cash From Operating Activities	-$783.6K	-$5.672M	-$10.30M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2023Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
CY2022	QLGN	Noncontrolling Interest Adjustments Relating To Stockbased Compensation And Other NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther		usd
CY2022	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt		usd
CY2022	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	QLGN	Proceeds From Issuance Of Convertible Debt ProceedsFromIssuanceOfConvertibleDebt		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	QLGN	Fractional Share Payments Related To Reverse Stock Split FractionalSharePaymentsRelatedToReverseStockSplit		usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease		usd
CY2023	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
CY2022	QLGN	Redemption Of Convertible Debt Into Common Stock RedemptionOfConvertibleDebtIntoCommonStock		usd
CY2022	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock		usd
CY2023	QLGN	Fair Value Of Warrant Modifications Pursuant To Securities Purchase Agreeement FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement		usd
CY2023	QLGN	Fair Value Of Warrant Modifications For Business Acquisition FairValueOfWarrantModificationsForBusinessAcquisition		usd
CY2023Q4	us-gaap	Receivable Investment Sale ReceivableInvestmentSale		usd
CY2022Q4	us-gaap	Receivable Investment Sale ReceivableInvestmentSale		usd
CY2022Q4	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses		usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
CY2023	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
CY2023	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2022	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity File Number EntityFileNumber	001-37428
CY2023	dei	Entity Registrant Name EntityRegistrantName	Qualigen Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
CY2023	dei	City Area Code CityAreaCode	(760)
CY2023	dei	Local Phone Number LocalPhoneNumber	452-8111
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	QLGN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4570535	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6307371	shares
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash Cash	401803	usd
CY2022Q4	us-gaap	Cash Cash	3165985	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	764964	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1366704	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6287849	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1166767	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10820538	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26242	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	866481	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	8236711	usd
CY2023Q4	us-gaap	Assets Assets	2033248	usd
CY2022Q4	us-gaap	Assets Assets	19083491	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2222983	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	619568	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	560006	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	864559	usd
CY2023Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	54600	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	788100	usd
CY2022Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2834547	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1299216	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	60197	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3441198	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4136805	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8608169	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1708732	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4136805	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10316901	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5362128	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5362128	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4210737	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4210737	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	43262	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42110	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	114655565	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110528050	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50721	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116802384	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103385172	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2103557	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7235709	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1530881	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2103557	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2033248	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19083491	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6095607	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10274600	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5209250	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4486120	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	11304857	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14760720	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11304857	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14760720	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2035469	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	907203	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1524722	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-34397	usd
CY2023	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1077287	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-625653	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-21747	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	38994	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1174946	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	872806	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12479803	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13887914	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4793	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6548	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12475010	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13894462	usd
CY2023	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-683008	usd
CY2022	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-7140181	usd
CY2023	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	602232	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1285240	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-7140181	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13760250	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-343038	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2394100	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13417212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18640543	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.46
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.46
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.62
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.62
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.19
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.19
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-1.24
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.24
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5072709	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5072709	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3840340	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3840340	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-13760250	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	119473	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50721	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13640777	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20983922	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-304735	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2394100	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13336042	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18589822	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1112582	usd
CY2023	QLGN	Stock Issued During Period Value Redemptions Of Convertible Debt Into Common Stock StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock	254316	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	7945	usd
CY2023	QLGN	Fair Value Of Warrant Reclassified From Liabilities To Equity FairValueOfWarrantReclassifiedFromLiabilitiesToEquity	1626694	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1107830	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	148070	usd
CY2023	QLGN	Deconsolidation Of Discontinued Operations DeconsolidationOfDiscontinuedOperations	-1367334	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13760250	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2103557	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8031	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5484044	usd
CY2022	QLGN	Stock Issued During Period Value Common Stock And Prefunded Warrants Issued For Business Acquisition StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition	7626142	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50721	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	67370	usd
CY2022	QLGN	Fair Value Of Warrant Modification For Business Acquisition FairValueOfWarrantModificationForBusinessAcquisition	696	usd
CY2022	QLGN	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits	-505	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13760250	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1285240	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-7140181	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12475010	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13894462	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4495	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12165	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1098533	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4765276	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2035469	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-906345	usd
CY2023	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt	-1077287	usd
CY2023	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt	-1469640	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-625653	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-21747	usd
CY2023	QLGN	Fair Value Of Warrant Modification For Professional Services FairValueOfWarrantModificationForProfessionalServices	7945	usd
CY2022	QLGN	Fair Value Of Warrant Modification For Professional Services FairValueOfWarrantModificationForProfessionalServices	67370	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	264741	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126985	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1603422	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-43440	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-227101	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-472441	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9093599	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10598862	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1210664	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2648679	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10304263	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13247541	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	4215943	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-183763	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4215943	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-183763	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7173	usd
CY2022	QLGN	Proceeds From Issuance Of Convertible Debt ProceedsFromIssuanceOfConvertibleDebt	2903847	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	550000	usd
CY2022	QLGN	Fractional Share Payments Related To Reverse Stock Split FractionalSharePaymentsRelatedToReverseStockSplit	505	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-550000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2910515	usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000.0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-550000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2910515	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6638320	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10520789	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22639	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3165985	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9174383	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3874138	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8363890	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3874138	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401803	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3165985	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5571	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5571	usd
CY2023	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease	83281	usd
CY2022	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
CY2023	QLGN	Redemption Of Convertible Debt Into Common Stock RedemptionOfConvertibleDebtIntoCommonStock	254316	usd
CY2023	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock	1112582	usd
CY2022	QLGN	Fair Value Of Warrant Modifications Pursuant To Securities Purchase Agreeement FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement	9439	usd
CY2022	QLGN	Fair Value Of Warrant Modifications For Business Acquisition FairValueOfWarrantModificationsForBusinessAcquisition	33543	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	These warrants were subsequently exercised on September 13, 2022.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zxiaUaiQGjf3">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2023Q4	us-gaap	Cash Cash	400000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10300000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13200000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	566011	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1329034	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	25053	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	37670	usd
CY2023Q4	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses	173900	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	764964	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1366704	usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2023Q4	QLGN	Longterm Research And Development Deposits LongtermResearchAndDevelopmentDeposits	416481	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	866481	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6287849	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	346896	shares
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	8236711	usd
CY2022Q4	QLGN	Total Assets Of Discontinued Operations TotalAssetsOfDiscontinuedOperations	14524560	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3441198	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1708732	usd
CY2022Q4	QLGN	Total Liabilities Ofdiscontinued Operations TotalLiabilitiesOfdiscontinuedOperations	5149930	usd
CY2023	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-683008	usd
CY2022	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-7140181	usd
CY2023	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	602232	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1285240	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-7140181	usd
CY2023Q3	QLGN	Purchase Price PurchasePrice	4900000	usd
CY2023Q3	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2023	QLGN	Disposal Group Including Discontinued Operation Fairvalue Of Consideration Received DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived	5489337	usd
CY2023	QLGN	Disposal Group Including Discontinued Operation Working Capital Adjustment DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment	235402	usd
CY2023Q4	QLGN	Disposal Group Including Discontinued Operation Total Assets DisposalGroupIncludingDiscontinuedOperationTotalAssets	-4225562	usd
CY2023Q4	QLGN	Disposal Group Including Discontinued Operation Total Liabilities DisposalGroupIncludingDiscontinuedOperationTotalLiabilities	3005407	usd
CY2023	QLGN	Disposal Group Including Discontinued Operation Transaction Expenses DisposalGroupIncludingDiscontinuedOperationTransactionExpenses	-627806	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	3876778	usd
CY2023Q4	QLGN	Disposal Group Including Discontinued Operation Gain Loss DisposalGroupIncludingDiscontinuedOperationGainLoss	17000	usd
CY2023Q4	QLGN	Accrued Compensation AccruedCompensation	129499	usd
CY2022Q4	QLGN	Accrued Compensation AccruedCompensation	70000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10004	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2829	usd
CY2023Q4	QLGN	Accrued License Fees AccruedLicenseFees	32975	usd
CY2022Q4	QLGN	Accrued License Fees AccruedLicenseFees	150130	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1215	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1247	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	121775	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	136203	usd
CY2023Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	104402	usd
CY2022Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	329412	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	151286	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	165040	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8850	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9698	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	560006	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	864559	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	247625	shares
CY2022Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	3622647	usd
CY2023	QLGN	Fair Value Of Warrant Liabilities On To Equity FairValueOfWarrantLiabilitiesOnToEquity	-1626694	usd
CY2023	QLGN	Fair Value Of Warrant Liabilities Loss On Debt Extinguishment FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment	94116	usd
CY2023	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-2035469	usd
CY2023Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	54600	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1100000	usd
CY2023	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	1500000	usd
CY2023	QLGN	Debt Redemption Amount In Cash DebtRedemptionAmountInCash	550000	usd
CY2023	QLGN	Debt Redemption Amount In Common Stock DebtRedemptionAmountInCommonStock	220000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1400000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	100000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13417212	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18640543	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5072709	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3840340	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5072709	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3840340	shares
CY2022Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	96558	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5781161	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5781161	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y1M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1098533	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5484044	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	219101	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	40.70
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	696	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12479803	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13887914	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12479803	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13887914	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0176	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0750	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.0064	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.0209	pure
CY2023	QLGN	Effective Income Tax Rate Reconciliation Non Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration	-0.0526	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation Non Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration	-0.1988	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0292	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0371	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000	pure
CY2023	QLGN	Effective Income Tax Rate Reconciliation Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationFairValueOfWarrant	0.0335	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationFairValueOfWarrant	0.0000	pure
CY2023	QLGN	Effective Income Tax Rate Reconciliation Tax Impact Of Convertible Debenture EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture	-0.0546	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation Tax Impact Of Convertible Debenture EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture	0.0137	pure
CY2023	QLGN	Effective Income Tax Rate Reconciliation Tax Impact Of Divestiture EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture	-2.2926	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation Tax Impact Of Divestiture EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture	0.0401	pure
CY2023	QLGN	Effective Income Tax Rate Reconciliation True Up EffectiveIncomeTaxRateReconciliationTrueUp	-0.1065	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation True Up EffectiveIncomeTaxRateReconciliationTrueUp	0.0224	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.2228	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1791	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0004	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0005	pure
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-10000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-5000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	23128000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-236000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4697000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2252000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	27825000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2488000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	27825000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2488000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8644000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32587000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4970000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7857000	usd
CY2023Q4	QLGN	Defferd Tax Assets Accrued Expenses DefferdTaxAssetsAccruedExpenses	68000	usd
CY2022Q4	QLGN	Defferd Tax Assets Accrued Expenses DefferdTaxAssetsAccruedExpenses	1020000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3004000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3069000	usd
CY2023Q4	QLGN	Deferred Tax Assets Research And Development Expenses DeferredTaxAssetsResearchAndDevelopmentExpenses	1102000	usd
CY2022Q4	QLGN	Deferred Tax Assets Research And Development Expenses DeferredTaxAssetsResearchAndDevelopmentExpenses	1196000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	280000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	17788000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	46009000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	13000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	382000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	395000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17788000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45614000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17788000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45614000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	15942000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	78693000	usd
CY2023	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite life for state tax purposes
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd

Files In Submission

Name	View Source	Status
0001493152-24-013400-index-headers.html	Edgar Link	pending
0001493152-24-013400-index.html	Edgar Link	pending
0001493152-24-013400.txt	Edgar Link	pending
0001493152-24-013400-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
logo_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qlgn-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
qlgn-20231231_cal.xml	Edgar Link	unprocessable
qlgn-20231231_def.xml	Edgar Link	unprocessable
qlgn-20231231_lab.xml	Edgar Link	unprocessable
qlgn-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

2024 Q1 Form 10-K Financial Statement

#000149315224013400 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN Qualigen Therapeutics, Inc. Stock $qlgn

2024 Q1 Form 10-K Financial Statement

#000149315224013400 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn